Κατάλογος ενδεικτικών δημοσιεύσεων του τμήματος Ιατρικής ΑΠΘ σε διεθνή επιστημονικά περιοδικά κατά τα τελευταία 5 έτη.
Export 93 results:
Συντάκτης Τίτλος Τύπος [ Έτος] Φίλτρα: Συντάκτης is Anastasilakis, Athanasios D [Clear All Filters]
Association of activins, follistatins and inhibins with incident hip fracture in women with postmenopausal osteoporosis: a proof of concept, case-control study..
Endocrine. 81(3), 573-578.
(2023). The Five-Year Effect of a Single Zoledronate Infusion on Bone Mineral Density Following Denosumab Discontinuation in Women with Postmenopausal Osteoporosis..
Calcif Tissue Int.
(2023). Lipid Profile after Pharmacologic Discontinuation and Restoration of Menstruation in Women with Endometriosis: A 12-Month Observational Prospective Study..
J Clin Med. 12(16),
(2023). The relationship between length of denosumab treatment for postmenopausal osteoporosis and serum TRAcP5b measured six months after the last injection..
Osteoporos Int.
(2023).
(2023). Wnt/beta-catenin signaling inhibitors and nonalcoholic fatty liver disease: Potential therapeutic implications..
Hepatobiliary Pancreat Dis Int.
(2023). Activins, follistatins and inhibins in postmenopausal osteoporosis: A proof of concept, case-control study..
Metabolism. 141, 155397.
(2022). The effect of pharmacological cessation and restoration of menstrual cycle on bone metabolism in premenopausal women with endometriosis..
Bone. 158, 116354.
(2022). Nonalcoholic fatty liver disease and osteoporosis: A potential association with therapeutic implications..
Diabetes Obes Metab. 24(9), 1702-1720.
(2022).
(2021).
Comparative Effect of Zoledronate at 6 Versus 18 Months Following Denosumab Discontinuation..
Calcif Tissue Int.
(2021). The duration of denosumab treatment and the efficacy of zoledronate to preserve bone mineral density after its discontinuation..
J Clin Endocrinol Metab.
(2021). Efficacy of Antiosteoporotic Medications in Patients With Rebound-Associated Fractures After Denosumab Discontinuation..
J Clin Densitom.
(2021). Irisin in nonalcoholic fatty liver disease: Need for an updated meta-analysis..
Metabolism. 121, 154818.
(2021). Postmenopausal osteoporosis coexisting with other metabolic diseases: Treatment considerations..
Maturitas. 147, 19-25.
(2021). Ιrisin levels in postmenopausal women with an incident hip fracture..
Endocrine. 73(3), 719-722.
(2021). Combination and sequential treatment in women with postmenopausal osteoporosis..
Expert Opin Pharmacother. 21(4), 477-490.
(2020). Obesity, osteoporosis and bone metabolism..
J Musculoskelet Neuronal Interact. 20(3), 372-381.
(2020).
(2020).
(2020). Asymptomatic and normocalcemic hyperparathyroidism, the silent attack: a combo-endocrinology overview..
Hormones (Athens). 18(1), 65-70.
(2019). Bone disease following solid organ transplantation: A narrative review and recommendations for management from The European Calcified Tissue Society..
Bone. 127, 401-418.
(2019). Circulating noggin levels following treatment with denosumab or teriparatide in postmenopausal women with low bone mass..
J Musculoskelet Neuronal Interact. 19(3), 253-257.
(2019).
(2019).
(2019). Σελίδες
- 1
- 2
- 3
- 4
- επόμενη ›
- τελευταία »